Arsenic trioxide (ATO), which is clinically used to treat promyelocytic leukemia and multiple myeloma, proteasome inhibitors, flavonoids, cyclopentenone prostaglandins, and glucocorticoids also have inhibitory effects on NFkB [18]. Here, NFKB1 is linked to acute promyelocytic leukemia.